Zarour HM - Search Results

1

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Davar D, et al. Among authors: zarour hm. J Clin Oncol. 2018 Oct 25;36(35):JCO1800632. doi: 10.1200/JCO.18.00632. Online ahead of print. J Clin Oncol. 2018. PMID: 30359157 Free PMC article.

2

Microbiome-derived metabolites counteract tumor-induced immunosuppression and boost immune checkpoint blockade.

Zarour HM. Zarour HM. Cell Metab. 2022 Dec 6;34(12):1903-1905. doi: 10.1016/j.cmet.2022.11.010. Cell Metab. 2022. PMID: 36476933 Free article.

3

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.

Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Zarour HM, et al. Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5. doi: 10.1073/pnas.97.1.400. Proc Natl Acad Sci U S A. 2000. PMID: 10618430 Free PMC article.

4

Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading.

Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ. Ranieri E, et al. Immunol Invest. 2000 May;29(2):121-5. doi: 10.3109/08820130009062294. Immunol Invest. 2000. PMID: 10854179 No abstract available.

5

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.

Zarour HM, Storkus WJ, Brusic V, Williams E, Kirkwood JM. Zarour HM, et al. Cancer Res. 2000 Sep 1;60(17):4946-52. Cancer Res. 2000. PMID: 10987311

6

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.

Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R. Kirkwood JM, et al. Among authors: zarour hm. Cancer. 2002 Sep 1;95(5):1101-12. doi: 10.1002/cncr.10775. Cancer. 2002. PMID: 12209697 Free article. Clinical Trial.

7

Melanoma vaccines: early progress and future promises.

Zarour HM, Kirkwood JM. Zarour HM, et al. Semin Cutan Med Surg. 2003 Mar;22(1):68-75. doi: 10.1053/sder.2003.50006. Semin Cutan Med Surg. 2003. PMID: 12773015 Review.

8

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

Mandic M, Almunia C, Vicel S, Gillet D, Janjic B, Coval K, Maillere B, Kirkwood JM, Zarour HM. Mandic M, et al. Among authors: zarour hm. Cancer Res. 2003 Oct 1;63(19):6506-15. Cancer Res. 2003. PMID: 14559844

9

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.

Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM. Mandic M, et al. Among authors: zarour hm. J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751. J Immunol. 2005. PMID: 15661941

10

Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.

Janjic B, Andrade P, Wang XF, Fourcade J, Almunia C, Kudela P, Brufsky A, Jacobs S, Friedland D, Stoller R, Gillet D, Herberman RB, Kirkwood JM, Maillere B, Zarour HM. Janjic B, et al. Among authors: zarour hm. J Immunol. 2006 Aug 15;177(4):2717-27. doi: 10.4049/jimmunol.177.4.2717. J Immunol. 2006. PMID: 16888034

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

84 results

Search Page

Filters